Meredith M. Regan, ScD

Publications

• Colleoni M, Giobbie-Hurder A, Regan MM, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Láng I, Smith I, Chirgwin J, Pienkowski T, Wardley A, Price KN, Gelber RD, Coates AS, Goldhirsch A.Analyses Adjusting for Selective Crossover Show Impr
  21321298
• Misra D, Xie W, Regan MM, Ross RW, Lee GS, Germain D, Kantoff PW, Oh WK.Germline CAG repeat length of the androgen receptor and time to progression in patients with prostate cancer treated with androgen deprivation therapy.BJU Int. 2011 Mar 16.
  21410629
• Pomerantz M, Werner L, Xie W, Regan MM, Lee GS, Sun T, Evan C, Petrozziello G, Nakabayashi M, Oh WK, Kantoff PW, Freedman ML.Association of prostate cancer risk loci with disease aggressiveness and prostate cancer-specific mortality.Cancer Prev Res (Phila
  21367958
• Viale G, Regan MM, Dell'orto P, Mastropasqua MG, Maiorano E, Rasmussen BB, Macgrogan G, Forbes JF, Paridaens RJ, Colleoni M, Láng I, Thürlimann B, Mouridsen H, Mauriac L, Gelber RD, Price KN, Goldhirsch A, Gusterson BA, Coates AS, .Which patients
  21335417
• Aebi S, Sun Z, Braun D, Price KN, Castiglione-Gertsch M, Rabaglio M, Gelber RD, Crivellari D, Lindtner J, Snyder R, Karlsson P, Simoncini E, Gusterson BA, Viale G, Regan MM, Coates AS, Goldhirsch A.Differential efficacy of three cycles of CMF followed by
  21282282
• San Francisco IF, Werner L, Regan MM, Garnick MB, Bubley G, DeWolf WC.Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance.J Urol. 2
  21167525
• Abe M, Xie W, Regan MM, King IB, Stampfer MJ, Kantoff PW, Oh WK, Chan JM.Single-nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer.BJU Int. 2011 Jan;107(1):126-134.
  20477822
• Drzymalski DM, Oh WK, Werner L, Regan MM, Kantoff P, Tuli S.Predictors of survival in patients with prostate cancer and spinal metastasis. Presented at the 2009 Joint Spine Section Meeting. Clinical article.J Neurosurg Spine. 2010 Dec;13(6):789-94.
  21121759
• Pomerantz MM, Shrestha Y, Flavin RJ, Regan MM, Penney KL, Mucci LA, Stampfer MJ, Hunter DJ, Chanock SJ, Schafer EJ, Chan JA, Tabernero J, Baselga J, Richardson AL, Loda M, Oh WK, Kantoff PW, Hahn WC, Freedman ML.Analysis of the 10q11 cancer risk locus imp
  21085629
• Oh WK, Vargas R, Jacobus S, Leitzel K, Regan MM, Hamer P, Pierce K, Brown-Shimer S, Carney W, Ali SM, Kantoff PW, Lipton A.Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer pa
  20862742
• Choueiri TK, Regan MM, Rosenberg JE, Oh WK, Clement J, Amato AM, McDermott D, Cho DC, Atkins MB, Signoretti S.Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving va
  20230385
• Reindollar RH, Regan MM, Neumann PJ, Levine BS, Thornton KL, Alper MM, Goldman MB.A randomized clinical trial to evaluate optimal treatment for unexplained infertility: the fast track and standard treatment (FASTT) trial.Fertil Steril. 2010 Aug;94(3):888-
  19531445
• Dandamundi B, Ghebremichael MS, Sosman JA, Regan MM, Atkins MB, Clark J, Dutcher JP, Curti BD, Vaishampayan UN, Ernstoff MS.A Phase II study of bevacizumab and high-dose IL-2 in patines with metastatic renal cell carcinoma: A Cytokine Working Group Study.
• Colleoni M, Cole BF, Viale G, Regan MM, Price KN, Maiorano E, Mastropasqua MG, Crivellari D, Gelber RD, Goldhirsch A, Coates AS, Gusterson BA.Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, nod
  20458051
• McDermott DF, Ghebremichael M, Signoretti S, Margolin KA, Clark J, Sosman JA, Dutcher JP, French M, Regan MM, Atkins MB.The high-dose aldesleukin (HD IL-2) "Select" Trial in patients with metastatic renal cell carcinoma (mRCC).Journal of Clinica
• Nakabayashi M, Oh WK, Jacobus S, Regan MM, Taplin ME, Kantoff PW, Rosenberg JE.Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer.BJU Int. 2010 May;105(10):1392-6.
  19863532
• Ahmadiyeh N, Pomerantz MM, Grisanzio C, Herman P, Jia L, Almendro V, He HH, Brown M, Liu XS, Davis M, Caswell JL, Beckwith CA, Hills A, Macconaill L, Coetzee GA, Regan MM, Freedman ML.8q24 prostate, breast, and colon cancer risk loci show tissue-specific
  20453196
• Maiorano E,Regan MM,Viale G,Mastropasqua MG,Colleoni M,Castiglione-Gertsch M,Price KN,Gelber RD,Goldhirsch A,Coates AS.Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: Results from two International Breast Cancer S
  19280340
• Regan MM, O'Donnell EK, Kelly WK, Halabi S, Berry W, Urakami S, Kikuno N, Oh WK.Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials.Ann Oncol. 2
  19633053
• Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK.Prognostic factors for overall survival in pa
  19826129
• Taplin ME, Regan MM, Ko YJ, Bubley GJ, Duggan SE, Werner L, Beer TM, Ryan CW, Mathew P, Tu SM, Denmeade SR, Oh WK, Sartor O, Mantzoros CS, Rittmaster R, Kantoff PW, Balk SP.Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone,
  19887483
• Eyre SJ, Ankerst DP, Wei JT, Nair PV, Regan MM, Bueti G, Tang J, Rubin MA, Kearney M, Thompson IM, Sanda MG.Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection.J Urol
  19836788
• Lu B, Maqsodi B, Yang W, McMaster GK, Perner S, Regan M, Bubley GJ, Balk SP, Rubin M, Sanda MG.Detection of TMPRSS2-ERG fusion gene expression in prostate cancer specimens by a novel assay using branched DNA.Urology. 2009 Nov;74(5):1156-61.
  19647299
• , Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith I, Mauriac L, Forbes JF, Price KN, Regan MM, Gelber RD, Coates AS.Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.N Engl J Med. 2009 Aug 20
  19692688
• Chan JM, Oh WK, Xie W, Regan MM, Stampfer MJ, King IB, Abe M, Kantoff PW.Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer.J Clin Oncol. 2009 Aug 1;27(22):3577-83.
  19528373
• Pomerantz MM, Ahmadiyeh N, Jia L, Herman P, Verzi MP, Doddapaneni H, Beckwith CA, Chan JA, Hills A, Davis M, Yao K, Kehoe SM, Lenz HJ, Haiman CA, Yan C, Henderson BE, Frenkel B, Barretina J, Bass A, Tabernero J, Baselga J, Regan MM, Manak JR, Shivdasani R
  19561607
• Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M, Wu T, Regan MM, Meyer CA, Carroll JS, Manrai AK, Jänne OA, Balk SP, Mehra R, Han B, Chinnaiyan AM, Rubin MA, True L, Fiorentino M, Fiore C, Loda M, Kantoff PW, Liu XS, Brow
  19632176
• Mosquera JM, Mehra R, Regan MM, Perner S, Genega EM, Bueti G, Shah RB, Gaston S, Tomlins SA, Wei JT, Kearney MC, Johnson LA, Tang JM, Chinnaiyan AM, Rubin MA, Sanda MG.Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy i
  19584163
• Regan MM.Statistical issues and challenges.Cancer Treat Res. 2009;151:77-90. Review.
  19593507
• Pomerantz MM, Beckwith CA, Regan MM, Wyman SK, Petrovics G, Chen Y, Hawksworth DJ, Schumacher FR, Mucci L, Penney KL, Stampfer MJ, Chan JA, Ardlie KG, Fritz BR, Parkin RK, Lin DW, Dyke M, Herman P, Lee S, Oh WK, Kantoff PW, Tewari M, McLeod DG, Srivastava
  19549893
• Schor-Bardach R,Alsop DC,Pedrosa I,Solazzo SA,Wang X,Marquis RP,Atkins MB,Regan M,Signoretti S,Lenkinski RE,Goldberg SN.Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in
  19474376
• Atkins MB, Choueiri TK, Cho D, Regan M, Signoretti S.Treatment selection for patients with metastatic renal cell carcinoma.Cancer. 2009 May 15;115(10 Suppl):2327-33. Review.
  19402069
• Cho DC,Puzanov I,Regan MM,Schwarzberg T,Seery V,Lee MY,Liu V,Bhatt R,Koon H,Mier JW,Sosman JA,Atkins MB,McDermott DF.Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell
  19238017
• Krzyzanowska MK,Regan MM,Powell M,Earle CC,Weeks JC.Impact of patient age and comorbidity on surgeon versus oncologist preferences for adjuvant chemotherapy for stage III colon cancer.J Am Coll Surg. 2009 Feb;208(2):202-9.
  19228531
• Choueiri TK,Xie W,D'Amico AV,Ross RW,Hu JC,Pomerantz M,Regan MM,Taplin ME,Kantoff PW,Sartor O,Oh WK.Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer trea
  19152438
• Sher DJ,Mantzoros C,Jacobus S,Regan MM,Lee GS,Oh WK.Absence of relationship between steroid hormone levels and prostate cancer tumor grade.Urology. 2009 Feb;73(2):356-61; discussion 361-2.
  19036418
• Keating NL,Stoeckert KA,Regan MM,DiGianni L,Garber JE.Physicians' experiences with BRCA1/2 testing in community settings.J Clin Oncol. 2008 Dec 10;26(35):5789-96.
  19001322
• Viale G,Giobbie-Hurder A,Regan MM,Coates AS,Mastropasqua MG,Dell'Orto P,Maiorano E,MacGrogan G,Braye SG,Ohlschlegel C,Neven P,Orosz Z,Olszewski WP,Knox F,Thurlimann B,Price KN,Castiglione-Gertsch M,Gelber RD,Gusterson BA,Goldhirsch A.Prognostic and p
  18981464
• Haram KM,Peltier HJ,Lu B,Bhasin M,Otu HH,Choy B,Regan M,Libermann TA,Latham GJ,Sanda MG,Arredouani MS.Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclin
  18668517
• Sher DJ,Oh WK,Jacobus S,Regan MM,Lee GS,Mantzoros C.Relationship between serum adiponectin and prostate cancer grade.Prostate. 2008 Oct 1;68(14):1592-8.
  18646046
• Regan MM, Pagani O, Walley B, Torrisi R, Perez EA, Francis P, Fleming GF, Price KN, Thurlimann B, Maibach R, Castiglione-Gertsch M, Coates AS, Goldhirsch A, Gelber RD.Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?.Ann O
  18325918
• Regan MM, Brick AJ, Choueiri TK, Clement JM, Kwabi C, Shah K, Amato A, McDermott DF, Atkins MB, Signoretti S.Carbonic anhydrase IX (CA IX) and pathologic features as predictors of outcome in patients (pts) with metastatic renal cell carcinoma (mRCC) recei
• Signoretti S,Regan M,Atkins M.Carbonic anhydrase IX as a predictive biomarker of response to kidney cancer therapy.BJU Int. 2008 Jun;101 Suppl 4:31-5. Review.
  18430120
• Arlen PM, Bianco F, Dahut WL, D'Amico A, Figg WD, Freedland SJ, Gulley JL, Kantoff PW, Kattan MW, Lee A, Regan MM, Sartor O.Prostate specific antigen working group guidelines on prostate specific antigen doubling time.J Urol. 2008 Jun;179(6):2181-6.
  18423743
• Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovacs A, Pillay K, Ohlschlegel C, Braye S, Grigolato P, Rusca T, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS.Chemoendocrine compared with e
  18349391
• Ross RW, Xie W, Regan MM, Pomerantz M, Nakabayashi M, Daskivich TJ, Sartor O, Taplin ME, Kantoff PW, Oh WK.Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antig
  18293426
• Ross RW, Oh WK, Xie W, Pomerantz M, Nakabayashi M, Sartor O, Taplin ME, Regan MM, Kantoff PW, Freedman M.Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer.J Clin Oncol.
  18281655
• Ravaioli A, Monti F, Regan MM, Maffini F, Mastropasqua MG, Spataro V, Castiglione-Gertsch M, Panzini I, Gianni L, Goldhirsch A, Coates A, Price KN, Gusterson BA, Viale G.p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-
  18272916
• Viale G, Regan MM, Mastropasqua MG, Maffini F, Maiorano E, Colleoni M, Price KN, Golouh R, Perin T, Brown RW, Kovacs A, Pillay K, Ohlschlegel C, Gusterson BA, Castiglione-Gertsch M, Gelber RD, Goldhirsch A, Coates AS.Predictive value of tumor Ki-67 expres
  18230798
• Nakabayashi M, Sartor O, Jacobus S, Regan MM, McKearn D, Ross RW, Kantoff PW, Taplin ME, Oh WK.Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer.BJU Int. 2
  18184327
• Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del Curto B, Henriksen KL, Mastropasqua MG, Price KN, Mery E, Lacroix-Triki M, Braye S, Altermatt HJ, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Gusterson BA, Thurlimann B, Coates AS, Viale G.
  18083065
• Xie W, Nakabayashi M, Regan MM, Oh WK.Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.Cancer. 2007 Dec 15;110(12):2709
  17960608
• Cho D, Signoretti S, Dabora S, Regan M, Seeley A, Mariotti M, Youmans A, Polivy A, Mandato L, McDermott D, Stanbridge E, Atkins M.Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma.Clin
  17956710
• Daskivich TJ, Regan MM, Oh WK.Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy.Urology. 2007 Sep;70(3):527-31.
  17905110
• Regan MM, Gelber RD.Using clinical trial data to tailor adjuvant treatments for individual patients.Breast. 2007 Dec;16 Suppl 2:S98-104.
  17719227
• Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell'Orto P, Rasmussen BB, Raffoul J, Neven P, Orosz Z, Braye S, Ohlschlegel C, Thurlimann B, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS.Prognostic and predictive
  17679725
• Hakime A, Hines-Peralta A, Peddi H, Atkins MB, Sukhatme VP, Signoretti S, Regan M, Goldberg SN.Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice.Radiology. 2007 Aug;244(2):464-70.
  17641366
• Nakabayashi M, Ling J, Xie W, Regan MM, Oh WK.Response to Vinorelbine With or Without Estramustine as Second-Line Chemotherapy in Patients with Hormone-Refractory Prostate Cancer.Cancer J. 2007 March/April;13(2):125-129.
  17476141
• Cho D, Signoretti S, Regan M, Mier JW, Atkins MB.The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer.Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):758s-763s. Review.
  17255306
• Kornblith AB, Powell M, Regan MM, Bennett S, Krasner C, Moy B, Younger J, Goodman A, Berkowitz R, Winer E.Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancer.Psychooncology. 2007 Oct;16(10):895-903.
  17245695
• Taplin ME, Xie W, Bubley GJ, Ernstoff MS, Walsh W, Morganstern DE, Regan MM.Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer.J Clin Oncol. 2006
  17135641
• Regan MM, Viale G, Mastropasqua MG, Maiorano E, Golouh R, Carbone A, Brown B, Suurküla M, Langman G, Mazzucchelli L, Braye S, Grigolato P, Gelber RD, Castiglione-Gertsch M, Price KN, Coates AS, Goldhirsch A, Gusterson B,.Re-evaluating adjuvant breast canc
  17077359
• Daskivich TJ, Regan MM, Oh WK.Prostate specific antigen doubling time calculation: not as easy as 1, 2, 4.J Urol. 2006 Nov;176(5):1927-37. Review.
  17070213
• McDermott DF, Regan MM, Atkins MB.Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials.Clin Genitourin Cancer. 2006 Sep;5(2):114-9. Review.
  17026799
• Kim WY, Safran M, Buckley MR, Ebert BL, Glickman J, Bosenberg M, Regan M, Kaelin WG.Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo.EMBO J. 2006 Oct 4;25(19):4650-62.
  16977322
• Nakabayashi M, Xie W, Regan MM, Jackman DM, Kantoff PW, Oh WK.Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer.Cancer. 2006 Sep 1;107(5):975-81.
  16862573
• Kornblith AB, Regan MM, Kim Y, Greer G, Parker B, Bennett S, Winer E.Cancer-related communication between female patients and male partners scale: a pilot study.Psychooncology. 2006 Sep;15(9):780-94.
  16308887
• Ford BM, Evans JS, Stoffel EM, Balmaña J, Regan MM, Syngal S.Factors associated with enrollment in cancer genetics research.Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1355-9.
  16835336
• Hines-Peralta A, Sukhatme V, Regan M, Signoretti S, Liu ZJ, Goldberg SN.Improved tumor destruction with arsenic trioxide and radiofrequency ablation in three animal models.Radiology. 2006 Jul;240(1):82-9.
  16720872
• San Francisco IF, Regan MM, Dewolf WC, Olumi AF.Low age adjusted free testosterone levels correlate with poorly differentiated prostate cancer.J Urol. 2006 Apr;175(4):1341-5; discussion 1345-6.
  16515994
• Nakabayashi M, Regan MM, Lifsey D, Kantoff PW, Taplin ME, Sartor O, Oh WK.Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer.BJU Int. 2005 Oct;96(6):783-6.
  16153200
• Atkins M, Regan M, McDermott D, Mier J, Stanbridge E, Youmans A, Febbo P, Upton M, Lechpammer M, Signoretti S.Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.Clin Cancer Res. 2005 May 15;11(10):3714-21.
  15897568
• McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, Tretter CP, Urba WJ, Smith JW, Margolin KA, Mier JW, Gollob JA, Dutcher JP, Atkins MB.Randomized phase III trial of high-dose interleukin-2
  15625368
• Bober SL, Hoke LA, Duda RB, Regan MM, Tung NM.Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors.J Clin Oncol. 2004 Dec 15;22(24):4951-7.
  15598980
• Atkins MB, Regan M, McDermott D.Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma.Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6342S-6S.
  15448028
• Tay MH, Kaufman DS, Regan MM, Leibowitz SB, George DJ, Febbo PG, Manola J, Smith MR, Kaplan ID, Kantoff PW, Oh WK.Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate.Ann Oncol. 2004 Jun;15(6):9
  15151957
• San Francisco IF, Regan MM, Olumi AF, DeWolf WC.Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen.J Urol. 2004 Apr;171(4):1492-9.
  15017206
• George DJ, Regan MM, Oh WK, Tay MH, Manola J, Decalo N, Duggan S, Dewolf WC, Kantoff PW, Bubley GJ.Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer.Urology. 2004 Feb;63(2):327-32.
  14972483
• San Francisco IF, Olumi AF, Yoon JH, Regan MM, DeWolf WC.Preoperative serum acid phosphatase and alkaline phosphatase are not predictors of pathological stage and prostate-specific antigen failure after radical prostatectomy.BJU Int. 2003 Dec;92(9):924-8.
  14632848
• Spentzos D, Mantzoros C, Regan MM, Morrissey ME, Duggan S, Flickner-Garvey S, McCormick H, DeWolf W, Balk S, Bubley GJ.Minimal effect of a low-fat/high soy diet for asymptomatic, hormonally naive prostate cancer patients.Clin Cancer Res. 2003 Aug 15;9(9):
  12960113
• Oh WK, Tully P, Kantoff PW, Regan MM.Physician attitudes toward cytotoxic chemotherapy use in patients with advanced prostate carcinoma.Cancer. 2003 May 1;97(9):2171-9.
  12712468
• Bubley GJ, Balk SP, Regan MM, Duggan S, Morrissey ME, Dewolf WC, Salgami E, Mantzoros C.Serum levels of insulin-like growth factor-1 and insulin-like growth factor-1 binding proteins after radical prostatectomy.J Urol. 2002 Nov;168(5):2249-52.
  12394769
• Parker RA, Regan MM, Reimann KA.Variability of viral load in plasma of rhesus monkeys inoculated with simian immunodeficiency virus or simian-human immunodeficiency virus: implications for using nonhuman primate AIDS models to test vaccines and therapeuti
  11602764
• Regan MM, Catalano PJ.Likelihood models for clustered binary and continuous outcomes: application to developmental toxicology.Biometrics. 1999 Sep;55(3):760-8.
  11315004